Cover Image
市場調查報告書

RNAII注射劑的中國市場:2010-2019年

Investigation Report on China ribonucleic acid II (RNAII) for Injection, 2010-2019

出版商 China Research and Intelligence 商品編碼 334095
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
RNAII注射劑的中國市場:2010-2019年 Investigation Report on China ribonucleic acid II (RNAII) for Injection, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 30 Pages
簡介

中國RNAII注射劑的開發正在急速發展中,其銷售額在2005年不到6000萬人民幣,但到2014年間已然以年複合成長率(CAGR)80%的速度擴大到5億人民幣。隨著經濟的發展生活型態的變化及嚴重的環境污染等問題,癌症發病率正在持續增加,新患者數每年均超過300萬人。此外中國更有超過9000萬名B型肝炎患者,在這些要素下,預測今後數年RNAII注射劑會持續成長。

本報告提供中國的RNAII注射劑的市場相關調查,提供您RNAII注射劑的功用·效果,中國市場中專利及核准狀況,銷售額·銷售量的變化與預測,價格趨勢,並彙整主要製造商與市場佔有率,競爭環境及其展望,主要製造商簡介等資料。

第1章 RNAII注射劑的相關概念

  • 功用·效果
  • 全球市場的銷售情形

第2章 中國的RNAII注射劑市場簡介

  • 專利·核準情況
  • 主要製造商
  • 市場規模

第3章 中國的RNAII注射劑銷售情形

  • 銷售額
    • 整體
    • 各地區
  • 銷售量
    • 整體
    • 各地區

第4章 中國的RNAII注射劑主要廠商的市場佔有率

  • 市場佔有率:銷售額
  • 市場佔有率:銷售量

第5章 中國的RNAII注射劑的各劑型佔有率

  • 各種劑型的市場佔有率:銷售額
  • 各種劑型的市場佔有率:銷售量

第6章 中國的醫院的RNAII注射劑參照價格

  • Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • Nanjing Xinbai Pharmaceutical Co., Ltd
  • Xinxiang Dongsheng Pharmaceutical Co., Ltd

第7章 中國市場中RNAII注射劑主要製造商

  • Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • Nanjing Xinbai Pharmaceutical Co., Ltd
  • Xinxiang Dongsheng Pharmaceutical Co., Ltd

第8章 中國的RNAII注射劑市場展望

  • 市場規模預測
  • 競爭情形的預測

圖表

目錄
Product Code: 1507256

RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. RNAII for injection can also be used for the treatment of various diseases caused by low immune function.

According to CRI's market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%.

With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Meanwhile, there are over 90 million hepatitis B patients in China too. Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China.

Readers can get at least the following information from this report:

  • market size of RNAII for injection in China
  • competitive landscape of RNAII for injection in Chinese market
  • price of RNAII for injection made by different enterprises in China
  • market outlook of RNAII for injection in China

The author suggests the following groups of people purchase this report:

  • manufacturers of immunomodulator
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of RNAII for Injection

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of RNAII for Injection in China

  • 2.1. Patent and Approval Status of RNAII for Injection in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of RNAII for Injection in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of RNAII for Injection in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of RNAII for Injection in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of RNAII for Injection in Chinese Hospitals in 2014

  • 6.1. Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • 6.2. Nanjing Xinbai Pharmaceutical Co., Ltd
  • 6.3. Xinxiang Dongsheng Pharmaceutical Co., Ltd

7. Major Manufacturers of RNAII for Injection in Chinese Market, 2010-2014

  • 7.1. Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
  • 7.2. Nanjing Xinbai Pharmaceutical Co., Ltd
  • 7.3. Xinxiang Dongsheng Pharmaceutical Co., Ltd

8. Market Outlook of RNAII for Injection in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of RNAII for Injection in China
  • Chart Sales Status of RNAII for Injection in China
  • Chart Sales Value of RNAII for Injection in China, 2010-2014
  • Chart Sales Value of RNAII for Injection in Some Regions in China, 2010-2014
  • Chart Sales Volume of RNAII for Injection in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of RNAII for Injection for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Nanjing Xinbai Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of RNAII for Injection Made by Xinxiang Dongsheng Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Price of RNAII for Injection Made by Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of RNAII for Injection Made by Nanjing Xinbai Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of RNAII for Injection Made by Xinxiang Dongsheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top